Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology guideline
Chaganti, Sridhar Fox, Christopher P Maybury, Bernard D Burton, Cathy Barrington, Sally F Illidge, Timothy Kalakonda, Nagesh Eyre, Toby A McKay, Pam Kuhnl, Andrea
Chaganti, Sridhar
Fox, Christopher P
Maybury, Bernard D
Burton, Cathy
Barrington, Sally F
Illidge, Timothy
Kalakonda, Nagesh
Eyre, Toby A
McKay, Pam
Kuhnl, Andrea
Affiliation
University Hospitals Birmingham NHS Foundation Trust; University of Nottingham; Leeds Teaching Hospitals NHS Trust; King's College London; Guy's and St Thomas' NHS Foundation Trust; University of Manchester; University of Liverpool; Oxford University Hospitals NHS Foundation Trust; Beatson West of Scotland Cancer Centre; King's College Hospital NHS Foundation Trust; University College London Hospitals NHS Foundation Trust; University of Southampton
Other Contributors
Publication date
2025-05-19
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Time to progression is the strongest predictor of outcome in relapsed diffuse large B-cell lymphoma. Second-line treatment with chimeric antigen receptor (CAR) T-cell therapy is recommended for patients with progression within 12 months of first-line chemoimmunotherapy. In patients with late relapse, platinum-based chemotherapy followed by high-dose chemotherapy with autologous stem cell rescue is recommended. In second relapse, CAR T-cell or CD3xCD20 bispecific antibody therapy is recommended in eligible patients. Other treatment options are available for less fit patients. Specific recommendations are made on diagnostic immunohistochemistry, bendamustine use and bridging to CAR T-cell therapy.
Citation
Chaganti S, Fox CP, Maybury BD, Burton C, Barrington SF, Illidge T, Kalakonda N, Eyre TA, McKay P, Kuhnl A, Cwynarski K, Davies AJ; BSH Committee. Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2025 Jun;206(6):1593-1603. doi: 10.1111/bjh.20129. Epub 2025 May 19.
Type
Article